BET Bromodomain Inhibitor iBET151 Impedes Human ILC2 Activation and Prevents Experimental Allergic Lung Inflammation

Group 2 innate lymphoid cells (ILC2) increase in frequency in eczema and allergic asthma patients, and thus represent a new therapeutic target cell for type-2 immune-mediated disease. The bromodomain and extra-terminal (BET) protein family of epigenetic regulators are known to support the expression...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Bernhard Kerscher, Jillian L. Barlow, Batika M. Rana, Helen E. Jolin, Mayuri Gogoi, Michelle A. Bartholomew, Deepali Jhamb, Ashutosh Pandey, David F. Tough, Antoon J. M. van Oosterhout, Andrew N. J. McKenzie
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Frontiers Media S.A. 2019-04-01
Reeks:	Frontiers in Immunology
Onderwerpen:	ILC2 Th2 asthma allergy bromodomain extra-terminal motif protein
Online toegang:	https://www.frontiersin.org/article/10.3389/fimmu.2019.00678/full
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!